Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision
Condition(s) studied
Investigational drug(s) / intervention(s)
Contact x-ray brachytherapy: With contact x-ray brachytherapy an intraluminal radiation boost up to 90 Gy is applied to the primary rectal tumour, with minimal collateral damage to the surrounding normal tissues due to minimal penetration of the 50 kVolt therapy.
Local excision: Local excision will basically be performed by the TAMIS-procedure (transanal minimally invasive surgery).
Study summary
The goal of this prospective phase II feasibility study is to evaluate two additional local treatment options in rectal cancer patients with a good clinical response after neoadjuvant (chemo)radiation: contact x-ray brachytherapy versus extension of the waiting interval with or without local excision, and to investigate which rate of organ preservation can be achieved.
Eligibility
Primary outcome measure(s)
- Rate of successful organ preservation — At one year following randomisation
Including an in-situ rectum (including patients subjected to local excision), no defunctioning stoma and absence of active loco-regional cancer failure (indicated as either local intraluminal tumour regrowth or regional recurrence in lymph nodes requiring TME-surgery)
Trial sites (7)
| Facility | City | Region | Status |
|---|---|---|---|
| Radbouw University Medical Centre | Nijmegen | Gelderland | Recruiting |
| Catharina Hospital | Eindhoven | North Brabant | Recruiting |
| Antoni van Leeuwenhoek | Amsterdam | North Holland | Recruiting |
| Deventer Hospital | Deventer | Overijssel | Recruiting |
| Isala | Zwolle | Overijssel | Recruiting |
| Medical Center Leeuwarden | Leeuwarden | Provincie Friesland | Recruiting |
| Ijsselland Hospital | Capelle aan den IJssel | South Holland | Recruiting |
More The Netherlands Cancer Institute trials in the Netherlands
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05772923 on ClinicalTrials.gov ↗ ← All trials in the Netherlands